These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 32561076)

  • 1. A step towards personalizing next line therapy for resected pancreatic and related cancer patients: A single institution's experience.
    Lowder CY; Dhir T; Goetz AB; Thomsett HL; Bender J; Tatarian T; Madhavan S; Petricoin EF; Blais E; Lavu H; Winter JM; Posey J; Brody JR; Pishvaian MJ; Yeo CJ
    Surg Oncol; 2020 Jun; 33():118-125. PubMed ID: 32561076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017.
    Ding D; Javed AA; Cunningham D; Teinor J; Wright M; Javed ZN; Wilt C; Parish L; Hodgin M; Ryan A; Judkins C; McIntyre K; Klein R; Azad N; Lee V; Donehower R; De Jesus-Acosta A; Murphy A; Le DT; Shin EJ; Lennon AM; Khashab M; Singh V; Klein AP; Roberts NJ; Hacker-Prietz A; Manos L; Walsh C; Groshek L; Brown C; Yuan C; Blair AB; Groot V; Gemenetzis G; Yu J; Weiss MJ; Burkhart RA; Burns WR; He J; Cameron JL; Narang A; Zaheer A; Fishman EK; Thompson ED; Anders R; Hruban RH; Jaffee E; Wolfgang CL; Zheng L; Laheru DA
    Cancer Lett; 2021 Jan; 497():221-228. PubMed ID: 33127389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine.
    Knudsen ES; O'Reilly EM; Brody JR; Witkiewicz AK
    Gastroenterology; 2016 Jan; 150(1):48-63. PubMed ID: 26385075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma.
    Blair AB; Groot VP; Gemenetzis G; Wei J; Cameron JL; Weiss MJ; Goggins M; Wolfgang CL; Yu J; He J
    J Am Coll Surg; 2018 Apr; 226(4):630-637.e1. PubMed ID: 29309945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatic cancer subtypes: a roadmap for precision medicine.
    Torres C; Grippo PJ
    Ann Med; 2018 Jun; 50(4):277-287. PubMed ID: 29537309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer.
    Malgerud L; Lindberg J; Wirta V; Gustafsson-Liljefors M; Karimi M; Moro CF; Stecker K; Picker A; Huelsewig C; Stein M; Bohnert R; Del Chiaro M; Haas SL; Heuchel RL; Permert J; Maeurer MJ; Brock S; Verbeke CS; Engstrand L; Jackson DB; Grönberg H; Löhr JM
    Mol Oncol; 2017 Oct; 11(10):1413-1429. PubMed ID: 28675654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive Cancer Panel Sequencing Defines Genetic Diversity and Changes in the Mutational Characteristics of Pancreatic Cancer Patients Receiving Neoadjuvant Treatment.
    Yoon KA; Woo SM; Kim YH; Kong SY; Lee MK; Han SS; Kim TH; Lee WJ; Park SJ
    Gut Liver; 2019 Nov; 13(6):683-689. PubMed ID: 30970447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive characterisation of compartment-specific long non-coding RNAs associated with pancreatic ductal adenocarcinoma.
    Arnes L; Liu Z; Wang J; Maurer C; Sagalovskiy I; Sanchez-Martin M; Bommakanti N; Garofalo DC; Balderes DA; Sussel L; Olive KP; Rabadan R
    Gut; 2019 Mar; 68(3):499-511. PubMed ID: 29440233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on the management of pancreatic cancer: surgery is not enough.
    Ansari D; Gustafsson A; Andersson R
    World J Gastroenterol; 2015 Mar; 21(11):3157-65. PubMed ID: 25805920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival Trends for Resectable Pancreatic Cancer Using a Multidisciplinary Conference: the Impact of Post-operative Chemotherapy.
    Syed AR; Carleton NM; Horne Z; Dhawan A; Bedi G; Kochhar G; Morrissey S; Williams H; Atkinson D; Schiffman S; Monga D; Lupetin A; Kirichenko A; Mitre M; Dhawan M; Kulkarni A; Thakkar S
    J Gastrointest Cancer; 2020 Sep; 51(3):836-843. PubMed ID: 31605289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial.
    Chantrill LA; Nagrial AM; Watson C; Johns AL; Martyn-Smith M; Simpson S; Mead S; Jones MD; Samra JS; Gill AJ; Watson N; Chin VT; Humphris JL; Chou A; Brown B; Morey A; Pajic M; Grimmond SM; Chang DK; Thomas D; Sebastian L; Sjoquist K; Yip S; Pavlakis N; Asghari R; Harvey S; Grimison P; Simes J; Biankin AV; ;
    Clin Cancer Res; 2015 May; 21(9):2029-37. PubMed ID: 25896973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diverse and precision therapies open new horizons for patients with advanced pancreatic ductal adenocarcinoma.
    Bai RL; Wang NY; Zhao LL; Zhang YF; Cui JW
    Hepatobiliary Pancreat Dis Int; 2022 Feb; 21(1):10-24. PubMed ID: 34538570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic Testing in Pancreatic Ductal Adenocarcinoma: Implications for Prevention and Treatment.
    Peters ML; Tseng JF; Miksad RA
    Clin Ther; 2016 Jul; 38(7):1622-35. PubMed ID: 27041411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of zebrafish embryos as avatar of patients with pancreatic cancer: A new xenotransplantation model towards personalized medicine.
    Di Franco G; Usai A; Funel N; Palmeri M; Montesanti IER; Bianchini M; Gianardi D; Furbetta N; Guadagni S; Vasile E; Falcone A; Pollina LE; Raffa V; Morelli L
    World J Gastroenterol; 2020 Jun; 26(21):2792-2809. PubMed ID: 32550755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical study of genomic drivers in pancreatic ductal adenocarcinoma.
    Barrett MT; Deiotte R; Lenkiewicz E; Malasi S; Holley T; Evers L; Posner RG; Jones T; Han H; Sausen M; Velculescu VE; Drebin J; O'Dwyer P; Jameson G; Ramanathan RK; Von Hoff DD
    Br J Cancer; 2017 Aug; 117(4):572-582. PubMed ID: 28720843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Germline Variants in Human DNA Damage Repair Genes and Response to Adjuvant Chemotherapy in Resected Pancreatic Ductal Adenocarcinoma.
    Hu H; Zhu Y; Pu N; Burkhart RA; Burns W; Laheru D; Zheng L; He J; Goggins MG; Yu J
    J Am Coll Surg; 2020 Nov; 231(5):527-535.e14. PubMed ID: 32659497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma.
    Tsai S; Christians KK; George B; Ritch PS; Dua K; Khan A; Mackinnon AC; Tolat P; Ahmad SA; Hall WA; Erickson BA; Evans DB
    Ann Surg; 2018 Oct; 268(4):610-619. PubMed ID: 30080723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Precision medicine in pancreatic cancer: treating every patient as an exception.
    Herbst B; Zheng L
    Lancet Gastroenterol Hepatol; 2019 Oct; 4(10):805-810. PubMed ID: 31511204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using next-generation sequencing to determine potential molecularly guided therapy options for patients with resectable pancreatic adenocarcinoma.
    Wright GP; Chesla DW; Chung MH
    Am J Surg; 2016 Mar; 211(3):506-11. PubMed ID: 26754455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High levels of nucleolar expression of nucleolin are associated with better prognosis in patients with stage II pancreatic ductal adenocarcinoma.
    Peng L; Liang J; Wang H; Song X; Rashid A; Gomez HF; Corley LJ; Abbruzzese JL; Fleming JB; Evans DB; Wang H
    Clin Cancer Res; 2010 Jul; 16(14):3734-42. PubMed ID: 20628027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.